核苷（酸）类似物单药和联合治疗慢性乙型肝炎疗效分析*

doi:10.3969/j.issn.1672-5069.2012.01.034

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (2): 169-171.doi: 10.3969/j.issn.1672-5069.2012.01.034

核苷（酸）类似物单药和联合治疗慢性乙型肝炎疗效分析^*

杨玥, 张振华, 李旭

230022 合肥市安徽医科大学第一附属医院感染病科

收稿日期:2011-08-15 出版日期:2012-04-10 发布日期:2017-03-07
通讯作者: 李旭,E-mail: aylixu@yahoo.com.cn
作者简介:杨玥女,23 岁,硕士研究生,主要研究方向为病毒性肝炎的基础和临床。
基金资助:
国家重大基础研究计划（973）项目（2009CB526411）; 高等学校博士学科点专项科研基金（20093420120005）

Received:2011-08-15 Online:2012-04-10 Published:2017-03-07

摘要/Abstract

摘要： 慢性乙型肝炎是我国最常见的慢性传染病之一,目前慢性乙型肝炎的治疗有两种不同方法,其中一种是口服抗HBV的核苷（酸）类似物长期有效地抑制乙肝病毒复制。本文将对近年核苷（酸）类似物的单药治疗和联合治疗的疗效及优劣进行综述。

杨玥, 张振华, 李旭. 核苷（酸）类似物单药和联合治疗慢性乙型肝炎疗效分析^*[J]. 实用肝脏病杂志, 2012, 15(2): 169-171.

[1] Ganem D,Prince AM. Hepatitis B virus infection-natural history and clinical conesquences. N Engl J Med,2004,350（11）:1118-1129.
[2] World Health Organization,Hepatitis B（[EB/OL]）. （Revised August 2008）. [2010-12-9]. Http:www.who.int/mediacentre/factsheets/fs204/en/.
[3] Bosch FX,Ribes J,Cleries R,et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis,2005,9（2）:191-211.
[4] Chen CJ,Yang HI,Su J,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA,2006,29（5）:65-73.
[5] Lok AS,Mcmahon BJ. Chronic hepatitis B:update 2009. Hepatology,2009,50（3）:661-662.
[6] Lok AS,Lai CL,Leung N,et al. Long-term safety of lamivudine treatm-ent in patients with chronic hepatitis B. Gastroenterology,2003,125 （6）:1714-1722.
[7] 贾克东,万里晖,刘南田,等. 拉米夫定治疗慢性乙型肝炎108 例疗效分析. 实用肝脏病杂志,2008,11（16）：408-409.
[8] Marcellin P,Chang TT,Lim SG,et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology,2008,48（3）:750-758.
[9] Gish RG,Lok AS,Chang TT,et al. Entecavir therapy for up to 96 weeks in patients with HBeAg positive chronic hepatitis B.Gastroenterology,2007,13（3）:1437-1444.
[10] Lai CL,Lim SG,Brown NA,et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology,2004,40（3）:719-726.
[11] Sung JJ,Lai JY,Zeuzem S,et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Hepatology,2008,48（5）:728-735.
[12] Wang LC,Chen EQ,Cao J,et al. De novo combination of lamivudine and adefovir versus entecavirmonotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol Int,2011,5（2）:671-676.
[13] Hadziyannis SJ,Papatheodoridis GV. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther,2004,2（4）:475-483.
[14] 霍丽亚.拉米夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化的临床观察. 实用肝脏病杂志,2008,11（6）:378.
[15] Liaw YF. Hepatitis B virus replication and liver disease progression:the impact of an tiviral therapy. Antivir Ther,2006,11（16）:669-679.
[16] Lai CL,Leung N,Teo EK,et al. A 1-year trial of telbivudine, lamivudine,and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology,2005,129 （2）:528-536.
[17] Ha NB,Garcia RT,Trinh HN,et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci,2011,56（8）:2423-2431.
[18] Dai CY,Chuang WL,Hsieh MY,et al. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Ras,2007,75（5）:146-151.
[19] 邵幼林,张锁才,陈良云,等. LAM耐药后ADV序贯治疗再耐药HBV变异株的动态变化.世界华人消化杂志,2010,18（18）：1895-1901.
[20] 郑建铭,张永信. 抗乙型肝炎病毒药物的合理应用. 上海医药,2010,31（9）：389-393.
[21] Rapti I,Dimou E,Mitsoula P,et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology,2007,45（2）:307-313.
[22] Yatsuji H,Suzuki F,Sezaki H,et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy:two year follow-up. Hepatology,2008,48（6）:923-931.
[23] Perrillo RP,Hann hw,Schiff E,et al.Extended treatment with lamivudine and adefovir dipivoxil inchronic hepatitis B patients with lamivudine resistance. Hepatology,2011,5（2）:654-663.
[24] Ash SH,Kweon YO,Paik SW,et al. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive,lamivudine-resistant chronic hepatitis B. Hepatol Int. 2011 Oct 12[Epub ahead of print].
[25] Zaaijer HL,Takkenberg RB,Weegink CJ,et al. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir. J Med Virol,2009,81（3）:413-416.
[26] Manolakopoulos S,Bethanis S,Koutsounas S,et al. Long-term therapy with adefovir dipvoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther,2008,27 （3）:266-273.
[27] Park JW,Kim HS,Seo DD,et al. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivud-ine resistance. J Viral Hepat,2011,18（10）:475-481.
[28] Hadziyannis SJ,Tassopoulos NC,Henthcote EJ,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology,2006,131（6）:1743-1751.
[29] Locarnini S,Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol,2006,44（2）:422-431.
[30] Wong CR,Trinh HN,Yip B,et al. High rate of complete viral suppression with combination therapy in patients with chronic hepatitis B and prior treatment failure. J Clin Gastroenterol,2011,45（10）:900-905.

核苷（酸）类似物单药和联合治疗慢性乙型肝炎疗效分析^*

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[8]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[9]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[10]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[11]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[12]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[13]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[14]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[15]	陈嵘, 黄美玲, 凌雪梅, 林小红, 曾俊, 黎云, 夏建红. 替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析*[J]. 实用肝脏病杂志, 2019, 22(5): 752-753.